TABLE 3.
Unstandardized coefficients |
Standardized coefficients |
||||
B | Standard error | Beta | t | P | |
Age (years) | −0.0.36 | 0.047 | −0.079 | −0.753 | 0.454 |
Gender (male) | 0.528 | 0.772 | 0.076 | 0.684 | 0.496 |
BMI (kg/m ) | 0.098 | 0.105 | 0.102 | 0.932 | 0.354 |
Use of NNRTI | −2.276 | 0.875 | −0.329 | −2.600 | 0.011 |
Use of PI | −0.815 | 0.447 | −0.230 | −1.821 | 0.072 |
Lipoatrophy | 1.035 | 0.870 | 0.144 | 1.190 | 0.238 |
Hepatitis C virus coinfection | 0.486 | 0.798 | 0.072 | 0.609 | 0.544 |
HIV-1 viral load (<200 copies/ml) | 0.932 | 0.821 | 0.136 | 1.136 | 0.260 |
CD4+ T-cell count (cells/mm ) | −0.001 | 0.001 | −0.130 | −1.170 | 0.246 |
Total cholesterol (mmol/l) | 0.457 | 0.322 | 0.179 | 1.418 | 0.160 |
HDL-cholesterol (mmol/l) | −0.529 | 0.831 | −0.074 | −0.636 | 0.526 |
Oxidized LDL (mmol/l) | −0.037 | 0.013 | −0.340 | −2.833 | 0.006 |
β-2-microglobulin (mg/l) | 0.176 | 0.292 | 0.176 | 0.550 | 0.550 |
Dependent variable: PON3 (mg/l) |
BMI, body mass index; NNRTI, nonnucleoside analogs reverse transcriptase inhibitor; PI, protease inhibitor.